tbuckley/cabot-search huggingface dataset:
Lasker award winners announced
Authors: W. A. Check
Journal: JAMA (1979)

The 34th annual Albert Lasker Medical Research Awards, presented Nov 15, honored three scientists who have contributed to two areas of widely divergent scope—the molecular structure of DNA and the anatomic basis of brain function. One award was shared by Walter Gilbert, PhD, and Frederick Sanger, PhD, for independently developing techniques that allow rapid determination of the nucleotide sequence of DNA. The other went to Roger W. Sperry, PhD, for his studies on the formation of nerve connections during development and the role of the right half of the brain in higher cognitive function. In addition, the Albert Lasker Special Public Service Award, presented this year for only the 11th time, honored Sir John Wilson, CBE, of England, for his efforts to establish worldwide programs for the prevention and treatment of blindness. Wilson, 60, who was himself blinded in a childhood accident, graduated with honors from Oxford University. After proposing
Abstract 17305: The ER Unfolded Protein Response Effector, ATF6, Promotes Proliferation and Maintains Pluripotency in Cardiac Stem Cells
Authors: Winston T Stauffer, Shirin Doroudgar, Haley N Stephens, Erik A Blackwood, Christopher C Glembotski
Journal: Circulation (2018)

Recent studies have suggested that multipotent stem cells residing in the adult heart, called cardiac stem cells (CSCs), mitigate damage in the infarcted or failing heart. Investigating the factors governing CSC proliferation and differentiation is key to understanding what role these cells play in the heart and in future therapeutic strategies. Additionally, activating transcription factor 6 (ATF6), an effector of the endoplasmic reticulum (ER) unfolded protein response (UPR), plays critical roles in development, as well as in the differentiation of certain stem cell types, though it has not been studied in this regard in the heart. Our lab has demonstrated that ATF6 in cardiac myocytes is cardioprotective in vivo during ischemia/reperfusion partly by virtue of its ability to induce an antioxidant gene program that reduces damaging reactive oxygen species (ROS). However, ATF6, and its involvement in antioxidant gene induction, have not been studied in CSCs. Therefore, here we hypothesized that activation of the ATF6 branch of the UPR in CSCs is important for their proliferation and differentiation, given that ROS is known to be essential for these processes. To address this hypothesis, we subjected cultured mouse CSCs to simulated ischemia and observed increased ATF6 target gene mRNA levels. This demonstrates that, despite their undifferentiated status, CSCs have a functional UPR, which can be activated in response to ischemic stress. ATF6 loss of function (LOF) in CSCs, via RNAi or chemical inhibitor, yielded a basal decrease in cell viability and an increase in several differentiation markers, similar to the effect of dexamethasone differentiation stimulus. Increased ROS was also observed in an ATF6 LOF model. Strikingly, cotreatment with a chemical ROS inhibitor significantly rescued cell viability and reduced markers of differentiation in CSCs with reduced ATF6 function. These results suggest that CSCs require a basal level of ATF6 activity to maintain their proliferation and pluripotentcy in vitro and that this is mediated by the role of ATF6 in the mitigation of ROS. This is an important finding given that stem cell expansion in vitro is a critical step in the characterization of stem cells and their use in many therapeutic treatment strategies.
Temporal and spatial localization of the angiopoietin-TIE-2 system after myocardial infarction in the rat: Evidence of a role for Ang-2 in angiogenesis Michael J.B. Kutryk, Reena Sandhu, Krystyna Teichert-Kuliszewska, Michael A. Kuliszewski, Sue Nag, Andrew I.M. Campbell, Duncan J. Stewart. Terrence Donnelly Heart Center, St. Michael's Hospital, Toronto, ON, Canada, Dept. of Neuropathology, University of Toronto Health Network, Toronto, ON, Canada
Journal: Journal of the American College of Cardiology (2001)
Community hospital and medical school linkage
Authors: P. R. Manning
Journal: JAMA (1979)

"It remains the last of the heavy metals in common clinical use," states a<i>British Medical Journal</i>"leader" (1:289-290, 1979) in a review of gold in the treatment of rheumatoid arthritis. Were it not for the qualifications of "common" and "clinical," the statement would be incorrect. Another heavy metal, platinum, is entering the therapeutic arena for use in the treatment of various malignant lesions. As in many other medical discoveries, serendipity played a part in the discovery of the therapeutic potential of platinum. In 1965 Rosenberg and associates<sup>1</sup>noted that discharge from a platinum electrode through a nutrient broth inhibited the replication of<i>Escherichia coli</i>. Since then many platinum compounds have been tested for antitumor action. Of these,<i>cis</i>-diamminedichloroplatinum proved to be the most effective. In addition to antineoplastic action, the biologic effects of<i>cis</i>-diamminedichloroplatinum include antimicrobial, mutagenic, and immunosuppressive properties. Its mechanism of action, although incompletely
Letter to the editor: Oral antivirals in treatment‐naïve chronic hepatitis C infection
Authors: Ankur Jindal
Journal: Hepatology (2022)

To the editor, We read with interest the randomized controlled trial by Sulkowski et al. comparing the safety and efficacy of oral antivirals in patients with HCV genotype 1. As well‐documented in previous studies,[1] treatment‐naïve patients with HCV genotype 1 and compensated liver disease are easy to treat. These individuals are expected to have sustained virological response (SVR) rates of over 95% with any of the combination therapy, namely, ledipasvir plus sofosbuvir (LDV/SOF), velpatasvir plus sofosbuvir (VEL/SOF), or elbasvir plus grazoprevir (EBR/GZR) for 12 weeks and glecaprevir plus pibrentasvir for 8 weeks.[1] In the presence of >95% SVR rates with these regimens, treatment options should be guided by local drug availability and cost. Therefore, the clinical relevance of this study in real‐life practice is debatable. The present study has certain limitations. Almost 15% patients in both treatment groups were lost to follow‐up after end of treatment. Approximately 40% patients intended for LDV/SOF therapy could not receive the desired treatment. Moreover, 26% patients on LDV/SOF received the suboptimal duration of treatment for ≤8 weeks. This led to bias in patient selection and interpretation of the results. It will be interesting to know the SVR rates in those who received the antivirals for up to 4 and 8 weeks. The rationale of combining ribavirin in treatment‐naïve patients with HCV genotype 1 and compensated liver disease is not clear, as it is not recommended by practice guidelines.[1,2] It is difficult to explain the low SVR rates of 80.7% in patients on EBR/GZR combined with ribavirin. In patients with genotype 1a infection, the presence of baseline NS5A resistance associate substitutions (RASs) that cause a large reduction in the activity of NS5A inhibitors (>5 fold) adversely affects response to some NS5A inhibitor–containing regimens.[3] Approximately 10% of patients in both groups had baseline RASs, and there were about 8%‐10% lower SVR rates in the presence of RASs. Given that baseline NS5A RASs are one of the strongest pretreatment predictors of therapeutic response, testing for these RASs on these regimens should be recommended to provide best possible treatment response, keeping in mind the expected high SVR rates (>95%). Use of VEL/SOF in the presence of baseline NASs might be beneficial. A previous study by Hezode et al. has shown that presence of baseline NS5A RASs did not influence the SVR12 rate for patients with genotype 1 treated with VEL/SOF.[4] CONFLICT OF INTEREST Nothing to report.
Differences in presentation and 1 year outcomes in coronary artery disease (CAD) patients of South Asian vs European ethnicity treated in an outpatient cardiology practice Narendra Singh, Milan K. Gupta, Arsh K. Jain, Frank Halperin, David Borts. Rouge Valley Health System, Toronto, ON, Canada, William Osler Health Centre, Brampton, ON, Canada
Journal: Journal of the American College of Cardiology (2001)
Body dysmorphia in common skin diseases: results of an observational, cross‐sectional multicentre study among dermatological outpatients in 17 European countries*
Authors: Christina Schut, Florence J. Dalgard, Anthony Bewley, Andrea W.M. Evers, Uwe Gieler, Lars Lien, Francesca Sampogna, Sonja Ständer, Lucía Tomás‐Aragonés, Nienke Vulink, Andrew Y. Finlay, Franz J. Legat, Geraldine Titeca, Gregor B. Jemec, Laurent Misery, Csanád Szabó, Vesna Grivcheva‐Panovska, Saskia Spillekom‐van Koulil, Flora Balieva, Jacek C. Szepietowski, Adam Reich, Bárbara Roque Ferreira, Andrey Lvov, Dmitry Romanov, Servando E. Marron, Tamara Gracia‐Cazaña, Ake Svensson, Ilknur K. Altunay, Andrew R. Thompson, Claudia Zeidler, Joerg Kupfer
Journal: British Journal of Dermatology (2022)

Body dysmorphic disorder (BDD) is a common psychiatric disorder associated with high costs for healthcare systems as patients may repeatedly ask for different, often not effective, interventions. BDD symptoms are more prevalent in patients with dermatological conditions than in the general population, but there are no large sample studies comparing the prevalence of BDD symptoms between patients with dermatological conditions and healthy skin controls.
Abstract 17171: Kruppel-Like Factor 4 Deletion Regulates Lymphatic Endothelial Cell Homeostasis
Authors: Victoria Mastej, Cassondra Axen, Kishore Wary
Journal: Circulation (2018)

Introduction and Hypothesis: Lymphatic vasculature exquisitely controls the clearance of metabolic end products, removal of bacterial endotoxins, and trafficking of immune cells. Signaling pathways that converge into endothelial cell kruppel-like factor 4 (KLF4) provide an atheroprotective role; however, the role of lymphatic endothelial cell (LEC)-KLF4 in these processes has not been clarified. Thus, we examined whether LEC-specific deletion of Klf4 alleles LECs. Methods and Results: After several generations of breeding, we transferred ROSA mT/mG (dual-fluorescent reporter allele mT/mG) to Prox1 CreERT2 (tamoxifen, TAM) inducible mice in C57 background to generate ROSA mT/mG ::Prox1 CreERT2 mice. In the next breeding scheme, ROSA mT/mG ::Prox1 CreERT2 female mice were crossed with male Klf4 fl/wt (Klf4 floxed allele) mice to generate heterozygous ROSA mT/mG ::Prox1 CreERT2 ::Klf4 fl/wt offspring (50%). Thereafter, we bred male ROSA mT/mG ::Prox1 CreERT2 ::Klf4 fl/wt with female ROSA mT/mG ::Prox1 CreERT2 ::Klf4 fl/wt to produce ROSA mT/mG ::Prox1 CreERT2 ::Klf4 fl/fl genotype (25%). These mice (12-14 weeks old) received TAM for five consecutive days, and on 21 st or 28 th day all mice were sacrificed. To confirm LEC Cre activation after TAM administration, we prepared cryosections of lung and the heart tissues. Mice receiving TAM showed lively and clear separation of green fluorescent protein (GFP) and tomato-Red colors, showing LEC specificity of Prox1 CreERT2 transgenic methodology. Cryosectioning combined with low- and high-resolution microscopy, and morphometric analyses of H&amp;E sections showed disruption of LEC function and integrity in these mice. Biochemical experiments underway will address the role of KLF4 in lymphatic vessels homeostasis. Conclusion: These results indicate a key role for Klf4 in the regulation of lymphatic vessels.
Animal Pain: Its Recognition, Alleviation, and Avoidance
Journal: JNCI Journal of the National Cancer Institute (1987)

Animal Pain: Its Recognition, Alleviation, and Avoidance JNCI: Journal of the National Cancer Institute, Volume 78, Issue 1, January 1987, Page 196, https://doi.org/10.1093/jnci/78.1.196 Published: 01 January 1987
Neurological Surgery
Authors: Robert H. Wilkins
Journal: JAMA (1992)

In their 1990 Contempo issue report, Carson and Brem emphasized that neurological surgery has rapidly evolved into a high-tech specialty.<sup>1</sup>They mentioned the development by neuroradiologists and neurosurgeons of the subspecialty of interventional neuroradiology and discussed the endovascular treatment of such lesions as intracranial aneurysms and arteriovenous malformations using balloons, glues, etc. Further refinements in equipment and technique have extended this work, with greater success and fewer complications. These interventionalists are now able to guide their catheters safely into small cerebral arterial branches to perform diagnostic and therapeutic maneuvers that include selective angiography; injection of an agent such as amobarbital to transiently alter the function of a focal brain region to establish the location of certain functions such as speech; injection of a chemotherapeutic drug into the direct arterial supply of a tumor; injection of an agent such as tissue plasminogen activator to lyse intravascular emboli and thrombi; injection
Introduction
Authors: Adam Smith, Melanie Brazil, Peter Kirkpatrick, Joanna Owens, Simon Frantz, Clare Ellis, Suzanne Farley, Daniel Jones, Susanne Harris, Claudia Bentley, Art Controller, Nicola Hawes, Sandra Clark, Judith Shadwell, Deputy Production, Simon Fenwick, Luisa Estanislao, Katherine Hodson, Sam Arr-Jones, Simone Zaremba, Amanda Ward, Mark Jones, Puja Kamdar, Clodagh Lyddy, Niamh Shields, Jane Walker, Susanne Harris Copy-Editing, Kelly Farrell, Stephen Advertising, Claire Hines
Journal: Nature Reviews Drug Discovery (2004)
The impact of directional coronary atherectomy prior to stenting versus stenting alone on net lumen gain: The paradoxical role of vessel size Issam Moussa, Antonio Colombo, Yoshio Kobayashi, Carlo Di Mario, Michael Collins, Milena Adamian, Edward Kreps, Jeffrey Moses. Lenox Hill Heart and Vascular Institute, New York, NY, Centro Cuore Columbus, Milan, Italy
Journal: Journal of the American College of Cardiology (2001)
Mitral leaflet 3-D kinematics during valve closure Tomasz A. Timek, David T. Lai, David Liang, Frederick A. Tibayan, Paul Dagum, G R. Green, George T. Daughters, Neil B. Ingels, Jr., D C. Miller. Stanford University, Stanford, CA, Research Institute of the Palo Alto Medical Foundation, Palo Alto, CA
Journal: Journal of the American College of Cardiology (2001)
Thrombospondin 1 induces apoptosis of human endothelial cells through activation of p38 mitogen activated protein kinase Rieko Kuwashima, Takahiro Katano, Eiichiro Takeo, Masayuki Katsumoto, Yasushi Toyota, Kozo Hayashi, Hideo Matsuura, Tetsuji Shingu. Hiroshima Univ. School of Medicine, Hiroshima, Japan
Journal: Journal of the American College of Cardiology (2001)
Long‐Term Recruitment of Endogenous M2 Macrophages by Platelet Lysate‐Rich Plasma Macroporous Hydrogel Scaffold for Articular Cartilage Defect Repair
Authors: Xiaoyun Pan, Shanshan Yuan, Xiaojie Xun, Zhiyuan Fan, Xinghe Xue, Changhuan Zhang, Jilong Wang, Junjie Deng
Journal: Advanced Healthcare Materials (2021)

After cartilage damage, a large number of monocytes/macrophages infiltrate into adjacent synovium and the resident macrophages in synovial tissue transform to activated macrophages (M1), which secrete pro-inflammatory cytokines to induce sustained inflammation and chondrocyte apoptotic. However, current clinical therapies for cartilage repair can rarely achieve long-term anti-inflammatory regulation and satisfactory outcomes. Herein, a platelet lysate-rich plasma macroporous hydrogel (PLPMH) scaffold with around 100 µm pore size and 1.25 MPa Young's modulus is developed to sustainedly recruit and polarize endogenous anti-inflammatory macrophages (M2) for improving cartilage defect repair. PLPMH scaffold can steadily release sphingosine1-phosphate and proteins via gradual degradation, thus inducing M2 macrophages migration or resting (M0) macrophages migration and then polarization to M2 phenotype, and improving the secretion of anti-inflammatory cytokines. Furthermore, PLPMH scaffold exhibits negligible inflammatory responses in vivo and promotes endogenous M2 macrophage infiltration in large numbers and long-time duration to provide a local anti-inflammatory microenvironment, which even lasts for 42 d. In a rabbit model of cartilage defect, PLPMH scaffold increases the ratio of M2 macrophages and improves cartilage tissue regeneration. These studies support that PLPMH scaffold may have a great potential in articular cartilage tissue engineering by providing an anti-inflammatory and pro-regenerative microenvironment.
Genetic Variations and the Risk for Alcohol-Induced Weakness of the Heart
Journal: Annals of Internal Medicine (2002)

Summaries for Patients3 September 2002Genetic Variations and the Risk for Alcohol-Induced Weakness of the HeartSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-137-5_Part_1-200209030-00003 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail What is the problem and what is known about it so far?Excessive alcohol consumption is known to cause weakness of the heart muscle, a condition called cardiomyopathy. However, because not all alcoholic persons develop cardiomyopathy, some researchers have suggested that a person's risk for this complication depends on his or her genetic make-up. Packets of genetic material, known as genes, occur in pairs, and each parent contributes half of the pair to the child. Although genes from each parent may be identical, they often differ slightly—these variations are called alleles. Alleles can lead to slight variations in the chemicals ... Author, Article, and Disclosure InformationAffiliations: The summary below is from the full report titled “Angiotensin-Converting Enzyme Gene Polymorphism Is Associated with Vulnerability to Alcoholic Cardiomyopathy.” It is in the 3 September 2002 issue of Annals of Internal Medicine (volume 137, pages 321-326). The authors are J Fernández-Solà, JM Nicolás, J Oriola, E Sacanella, R Estruch, E Rubin, and A Urbano-Márquez.Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians-American Society of Internal Medicine. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoAngiotensin-Converting Enzyme Gene Polymorphism Is Associated with Vulnerability to Alcoholic Cardiomyopathy Joaquim Fernández-Solà , Josep María Nicolás , Josep Oriola , Emilio Sacanella , Ramón Estruch , Emanuel Rubin , and Alvaro Urbano-Márquez Angiotensin-Converting Enzyme Gene Polymorphism Is Associated with Vulnerability to Alcoholic Cardiomyopathy Joaquim Fernández-Solà , Josep María Nicolás , Josep Oriola , Emilio Sacanella , Ramón Estruch , Emanuel Rubin , and Alvaro Urbano-Márquez Metrics 3 September 2002Volume 137, Issue 5_Part_1Page: I-44KeywordsAlcoholicsAlcoholsAllelesAngiotensin converting enzymeCardiomyopathiesGeneticsMuscle tissueMyocardiumPatient advocacyResearch laboratories ePublished: 3 September 2002 Issue Published: 3 September 2002 Copyright & PermissionsCopyright © 2002 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Sunitinib-Induced Myositis Detected on 18F-FDG PET/CT
Authors: Ritesh R. Suthar, Nilendu Purandare, Sneha Shah, Archi Agrawal, Ameya Puranik, Venkatesh Rangarajan
Journal: Clinical Nuclear Medicine (2022)

Sunitinib is one of the most commonly used multikinase inhibitors for metastatic renal cell carcinoma. Myositis is one of the rarest known adverse effects of sunitinib. Presenting herewith one such case with its relevant imaging findings on FDG PET/CT and ultrasound.
Potential bias in the use of combined end points in quality assessment of percutaneous coronary interventions: An analysis of the relationship between history of prior CABG and MACE Mauro Moscucci, David J. Malenka, David E. Wennberg, David Share, Michael J. O'Donnell, Anthony DeFranco, Eva Kline-Rogers, Adam B. Greenbaum, Ann Maxwell-Eward, William L. Meengs, Kim A. Eagle. University of Michigan Medical Center, Ann Arbor, MI
Journal: Journal of the American College of Cardiology (2001)
Should we pay donors to increase the supply of organs for transplantation? No
Authors: Jeremy Chapman
Journal: BMJ (2008)

Paymentfor livingkidney donation is illegal in most countries.<b> Arthur Matas</b> (doi: 10.1136/bmj.a157) believes that legalisation is needed to shorten waiting times, but <b>Jeremy Chapman</b> argues that it will reduce the supply of all organs
Metformin versus other oral agents: Does the choice of discharge diabetic medications predict mortality? results from a registry of 1,428 diabetic patients Farangis Lavasani, Joseph B. Muhlestein, Benjamin D. Horne, Robert R. Pearson, Tami L. Bair, Sunni K. Kim, Chloe A. Allen Maycock, Kirti Salunkhe, Dale G. Renlund, Jeffrey L. Anderson. LDS Hospital, Salt Lake City, UT
Journal: Journal of the American College of Cardiology (2001)
Error in Author’s Name
Journal: JAMA Network Open (2021)

Naveen Poonai, MSc, MD; Elizabeth C. Powell, MD; David Schnadower, MD, MPH; T. Charles Casper, PhD; Cindy G. Roskind, MD; Cody S. Olsen, MSc; Phillip I. Tarr, MD; Prashant Mahajan, MD, MPH, MBA; Alexander J. Rogers, MD; Suzanne Schuh, MD; Katrina F. Hurley, MD; Serge Gouin, MDCM; Cheryl Vance, MD; Ken J. Farion, MD; Robert E. Sapien, MD; Karen J. O’Connell, MD; Adam C. Levine, MD, MPH; Seema Bhatt, MD; Stephen B. Freedman, MDCM, MSc; Pediatric Emergency Care Applied Research Network (PECARN) and Pediatric Emergency Research Canada (PERC)
Correction:<i>COVID-19 lung injury as a primer for immune checkpoint inhibitors (ICIs)-related pneumonia in a patient affected by squamous head and neck carcinoma treated with PD-L1 blockade: a case report</i>
Authors: Andrew Kent, Eduardo Davila, Jitao Guo
Journal: Journal for ImmunoTherapy of Cancer (2021)

Correction: COVID-19 lung injury as a primer
Brain Gender
Authors: R. J. Bodnar
Journal: JAMA (2004)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal